myLaminin Perspectives

Learn the differences between CTMS, EDC, and eTMF and how these essential clinical trial systems work together to improve research operations, data quality, regulatory compliance, and study efficiency. This guide explains the role of each platform, their integration across the clinical trial lifecycle, and how myLaminin's Research Data Management platform combines CTMS capabilities, participant management, eTMF, protocol management, audit trails, and 21 CFR Part 11 compliant

Clinical trial start-up delays continue to impact site activation, budgets, and timelines due to fragmented workflows across feasibility, contracting, IRB/REB approvals, training, and system readiness. This article explains how CTMS platforms, integrated research systems, and AI-driven automation reduce inefficiencies by centralizing processes, improving visibility, and accelerating trial activation across global clinical research environments.

Rising clinical trial costs are driven by growing protocol complexity, recruitment challenges, site capacity limits, regulatory burdens, and expanding data demands. These inefficiencies strain sponsors and delay outcomes. By adopting quality-by-design, optimizing protocols, improving patient engagement, and leveraging integrated CTMS and RDM platforms, organizations can reduce costs, enhance compliance, and accelerate clinical research while maintaining data integrity.

Today’s research landscape is increasingly complex, requiring a flexible, integrated approach to cybersecurity, privacy, and ethics. myLaminin proposes a modern Research Security Office (RSO) framework with core protections—cybersecurity, data privacy, ethics, export controls, and research integrity—plus modular, discipline-specific components. This proactive model supports secure, ethical, and collaborative research across diverse domains.

By partnering with industry, HEIs can enhance cybersecurity, streamline compliance processes, and strengthen technology transfer mechanisms